Table 1 Descriptive data of study population
Author (year)/ Country | Study design | Age (years) mean ± SDM | Gender (male/female) n | Body mass index (kg/m2) mean ± SDM | Total number of subjects | OSA status (n) | Purpose of study | Surgery | Comparators | Oxford LOE |
|---|---|---|---|---|---|---|---|---|---|---|
Q 1. OSA vs. non-OSA | ||||||||||
Sudre [32] 2015 Brazil | RCT | IPG 37 ± 11 CG 36 ± 11 | IPG 49/151 CG 36/116 | IPG 46 ± 6 CG 44 ± 6 | 352 | Already diagnosed OSA (Interventional = 89, Control = 79) | Compared the effects of 2 protocols, Interventional (Remif, Roc, Sevo) vs. Control (Suf, Atracurium, Iso) on immediate recovery time and PPCs after bariatric surgery. | Laparotomy for gastric bypass | Interventional group vs. Control group | 2 |
Ahmad [30] 2009 US | Prospective Cohort | OSA 43 ± 10 Non-OSA 42 ± 12 | OSA 8/23 Non-OSA 0/9 | OSA 50 ± 9 Non-OSA 48 ± 6 | 40 | Diagnosed OSA (31) by PSG and Berlin questionnaire | To determine whether obese patients with OSA vs. non-OSA were at greater risk for postoperative hypoxemic episodes after bariatric surgery | Laparoscopic bariatric | OSA vs. non-OSA | 3 |
Pereira [31] 2013 Portugal | Prospective Observational | HR-OSA 63 ± 12 LR-OSA 48 ± 18 | HR-OSA 113/66 LR-OSA 33/128 | HR-OSA 28 ± 5 LR-OSA 24 ± 5 | 340 | STOP-Bang {If ≥3, HR-OSA (179) If 0–2, LR-OSA (161)} | To evaluate the STOP-Bang score in surgical patients in PACU. | Intra-abdominal/bariatric, musculoskeletal, Otolaryngologic | HR-OSA vs. LR-OSA | 3 |
Q 2. Sugammadex vs. Neostigmine | ||||||||||
Unal [33] 2015 Turkey | RCT | Group S (44 ± 9), Group N (46 ± 11) | Not mentioned | Group S 28 ± 3 Group N 28 ± 3 | 74 | Already diagnosed OSA (74) | To compare sugammadex and neostigmine for reversing rocuronium-induced NMB, PPCs s and costs in patients undergoing surgery for treatment of OSA. | Anterior palatoplasty; UPP; tonsillectomy+ UPP, septoplasty; tonsillectomy+ Lateral pharyngoplasty | Sugammadex vs neostigmine | 2 |
Llaurado [34] 2014 Spain | Cohort - Observational | SG 45 ± 35 HG 44 ± 31 | SG 32/68 HG 27/73 | SG 49 ± 27 HG 46 ± 24 | 320 | Already diagnosed OSA (SG = 74, HG = 61) | To determine whether sugammadex vs. neostigmine to reverse NMB could decrease adverse postoperative respiratory outcomes. | Laparoscopic bariatric | Sugammadex group vs. historical group (neostigmine) | 3 |